/

Sociétés

As

Non vérifié

AstraZeneca

Ce que nous écrivons

BiotechnologieIndustrieIndustrie pharmaceutiqueMédecine - DiversSanté

114 communiqués de presse

Voir tous les communiqués de presse

24/06/2026

Marché du travail

Industrie

Biotechnologie

Santé Publique

Santé

Industrie pharmaceutique

Oncologie

AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care

Source

Émetteur

1.00

0

12/06/2026

Hygiène alimentaire

Troisième âge

Médecine - Divers

Biotechnologie

Santé

Vitrines/Shopping

Industrie pharmaceutique

Oncologie

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

Source

Émetteur

1.00

0

02/06/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial

Source

Émetteur

1.00

0

01/06/2026

Science

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Oncologie

Événements

Industrie

IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial

Source

Émetteur

1.00

0

29/05/2026

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Industrie

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

Source

Émetteur

1.00

0

22/05/2026

Industrie

Science

Médecine - Divers

Hygiène alimentaire

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

Source

Émetteur

1.00

0

22/05/2026

Science

Médecine - Divers

Biotechnologie

Santé

Industrie pharmaceutique

Santé Publique

Oncologie

Événements

Industrie

AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026

Source

Émetteur

1.00

0

18/05/2026

BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

Source

Émetteur

1.00

0

16/05/2026

Industrie

Science

Médecine - Divers

Hygiène alimentaire

Biotechnologie

Santé

Industrie pharmaceutique

Oncologie

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

Source

Émetteur

1.00

0

14/05/2026

Industrie

Oncologie

Santé

Médecine - Divers

Science

Industrie pharmaceutique

Biotechnologie

Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0